These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31018868)

  • 1. Composed endotypes to guide antibiotic discontinuation in sepsis.
    Bermejo-Martin JF; Andaluz-Ojeda D; Martin-Fernandez M; Aldecoa C; Almansa R
    Crit Care; 2019 Apr; 23(1):140. PubMed ID: 31018868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers and clinical scores to identify patient populations at risk of delayed antibiotic administration or intensive care admission.
    Gonzalez Del Castillo J; Wilson DC; Clemente-Callejo C; Román F; Bardés-Robles I; Jiménez I; Orviz E; Dastis-Arias M; Espinosa B; Tornero-Romero F; Giol-Amich J; González V; Llopis-Roca F;
    Crit Care; 2019 Oct; 23(1):335. PubMed ID: 31665092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection.
    Stalenhoef JE; van Nieuwkoop C; Wilson DC; van der Starre WE; van der Reijden TJK; Delfos NM; Leyten EMS; Koster T; Ablij HC; van 't Wout JJW; van Dissel JT
    BMC Infect Dis; 2019 Feb; 19(1):161. PubMed ID: 30764769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Procalcitonin to guide antibiotic therapy in the ICU.
    Bréchot N; Hékimian G; Chastre J; Luyt CE
    Int J Antimicrob Agents; 2015 Dec; 46 Suppl 1():S19-24. PubMed ID: 26607343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis.
    Kip MM; Kusters R; IJzerman MJ; Steuten LM
    J Med Econ; 2015; 18(11):944-53. PubMed ID: 26105574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of procalcitonin testing to guide antibiotic treatment duration in critically ill patients: results from a randomised controlled multicentre trial in the Netherlands.
    Kip MMA; van Oers JA; Shajiei A; Beishuizen A; Berghuis AMS; Girbes AR; de Jong E; de Lange DW; Nijsten MWN; IJzerman MJ; Koffijberg H; Kusters R
    Crit Care; 2018 Nov; 22(1):293. PubMed ID: 30424796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials.
    Wirz Y; Meier MA; Bouadma L; Luyt CE; Wolff M; Chastre J; Tubach F; Schroeder S; Nobre V; Annane D; Reinhart K; Damas P; Nijsten M; Shajiei A; deLange DW; Deliberato RO; Oliveira CF; Shehabi Y; van Oers JAH; Beishuizen A; Girbes ARJ; de Jong E; Mueller B; Schuetz P
    Crit Care; 2018 Aug; 22(1):191. PubMed ID: 30111341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?
    Sridharan P; Chamberlain RS
    Surg Infect (Larchmt); 2013 Dec; 14(6):489-511. PubMed ID: 24274059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.
    Westwood M; Ramaekers B; Whiting P; Tomini F; Joore M; Armstrong N; Ryder S; Stirk L; Severens J; Kleijnen J
    Health Technol Assess; 2015 Nov; 19(96):v-xxv, 1-236. PubMed ID: 26569153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic role of procalcitonin (PCT) and MR-pro-Adrenomedullin (MR-proADM) in bacterial infections.
    Angeletti S; Spoto S; Fogolari M; Cortigiani M; Fioravanti M; De Florio L; Curcio B; Cavalieri D; Costantino S; Dicuonzo G
    APMIS; 2015 Sep; 123(9):740-8. PubMed ID: 26058482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procalcitonin-Guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients (PRODA): a Multi-Center Randomized Controlled Trial.
    Jeon K; Suh JK; Jang EJ; Cho S; Ryu HG; Na S; Hong SB; Lee HJ; Kim JY; Lee SM
    J Korean Med Sci; 2019 Apr; 34(14):e110. PubMed ID: 30977312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial.
    Elke G; Bloos F; Wilson DC; Brunkhorst FM; Briegel J; Reinhart K; Loeffler M; Kluge S; Nierhaus A; Jaschinski U; Moerer O; Weyland A; Meybohm P;
    Crit Care; 2018 Mar; 22(1):79. PubMed ID: 29562917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.
    Shehabi Y; Sterba M; Garrett PM; Rachakonda KS; Stephens D; Harrigan P; Walker A; Bailey MJ; Johnson B; Millis D; Ding G; Peake S; Wong H; Thomas J; Smith K; Forbes L; Hardie M; Micallef S; Fraser JF; ;
    Am J Respir Crit Care Med; 2014 Nov; 190(10):1102-10. PubMed ID: 25295709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Comparison of Procalcitonin Guidance Administer Antibiotics with Empiric Antibiotic Therapy in Critically Ill Patients Admitted in Intensive Care Unit.
    Najafi A; Khodadadian A; Sanatkar M; Shariat Moharari R; Etezadi F; Ahmadi A; Imani F; Khajavi MR
    Acta Med Iran; 2015; 53(9):562-7. PubMed ID: 26553084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
    de Jong E; van Oers JA; Beishuizen A; Vos P; Vermeijden WJ; Haas LE; Loef BG; Dormans T; van Melsen GC; Kluiters YC; Kemperman H; van den Elsen MJ; Schouten JA; Streefkerk JO; Krabbe HG; Kieft H; Kluge GH; van Dam VC; van Pelt J; Bormans L; Otten MB; Reidinga AC; Endeman H; Twisk JW; van de Garde EMW; de Smet AMGA; Kesecioglu J; Girbes AR; Nijsten MW; de Lange DW
    Lancet Infect Dis; 2016 Jul; 16(7):819-827. PubMed ID: 26947523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of procalcitonin in monitoring the antibiotic therapy in septic surgical patients].
    Pundiche M; Sârbu V; Unc OD; Grasa C; Martinescu A; Bădărău V; Durbală I; Sapte E; Pasăre R; Voineagu L; Iordache I; Vâncă A; Adam A
    Chirurgia (Bucur); 2012; 107(1):71-8. PubMed ID: 22480120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting.
    Albrich WC; Harbarth S
    Intensive Care Med; 2015 Oct; 41(10):1739-51. PubMed ID: 26194026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial.
    Nobre V; Harbarth S; Graf JD; Rohner P; Pugin J
    Am J Respir Crit Care Med; 2008 Mar; 177(5):498-505. PubMed ID: 18096708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Interleukin-6 a better predictor of successful antibiotic therapy than procalcitonin and C-reactive protein? A single center study in critically ill adults.
    Weidhase L; Wellhöfer D; Schulze G; Kaiser T; Drogies T; Wurst U; Petros S
    BMC Infect Dis; 2019 Feb; 19(1):150. PubMed ID: 30760225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procalcitonin: potential role in diagnosis and management of sepsis.
    Rowland T; Hilliard H; Barlow G
    Adv Clin Chem; 2015; 68():71-86. PubMed ID: 25858869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.